Skip to main content
Donate

Recruitment Open for Roche Aldebaran Study

Recruitment open for Roche Aldebaran study - 10-23-23

Recruitment is still open for the Aldebaran study, sponsored by Roche, to assess an investigational drug (called Alogabat) to potentially treat Angelman syndrome. While it does not involve replacing or unsilencing the UBE3Agene in individuals living with AS, it’s a mechanism aimed to help improve various symptoms of AS such as learning, sleep, and seizure control.

The study is looking for approximately 56 children and adolescents diagnosed with (genetically confirmed) deletion AS to participate in this study. Each child must be between the ages of 5 and 17 years old at the time they enter the study.

Participation will last for up to approximately 24 weeks in total, including screening, treatment, and follow-up periods. The treatment period will last for 12 weeks. The study consists of two consecutive parts – Part 1 and Part 2. Both parts will assess how safe and well-tolerated the investigational drug is, as well as how the body processes the drug.

Data from Part 1 will be used to determine which dose is used for each age group in Part 2. In addition, Part 2 will focus on assessing the investigational drug’s impact on brain waves. In both parts, participants will take the investigational drug once a day by mouth (tablet form), with or shortly after food. Tablets can be dispersed or hidden in food.

Please consult your physician if you are interested in participating in the study. Currently sites are open in New York, North Carolina, Illinois, Australia, France, Spain and Italy.

For more information, please click here.

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.